• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023

    7/28/23 7:05:00 AM ET
    $ARAV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARAV alert in real time by email

    HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the acceptance of two abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held October 20-24, 2023 in Madrid, Spain. Posters will feature clinical data from the Company's ongoing Phase 1b/2 trials of batiraxcept in clear cell renal cell carcinoma (ccRCC) and pancreatic adenocarcinoma (PDAC).

    Presentation Details:

    Title:Phase 1b/2 Study of Batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in Combination with Cabozantinib (Cabo) in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) who Failed First Line (1L) Therapy
    Presenter:Neil Shah, MBBS
    Abstract Number:2294



    Title:Phase 1b/2 Study of Batiraxcept (AVB-S6-500, BT) plus Nab-paclitaxel (NP) and Gemcitabine (G) as first-line treatment (1L) for metastatic pancreatic adenocarcinoma (PDAC)
    Presenter:Vaibhav Sahai, MBBS, MS
    Abstract Number:3218

    Posters will be available on the "Publications" section of the Aravive website at the start of the meeting.

    About Aravive

    Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. Batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the U.S. FDA for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase 3 trial in platinum resistant ovarian cancer (NCT04729608), a Phase 1b/2 trial in clear cell renal cell carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic adenocarcinoma (NCT04983407). The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Additional information at www.aravive.com.

    Investor Relations Contact:

    Corey Davis, Ph.D.

    LifeSci Advisors, LLC

    212-915-2577

    [email protected]



    Primary Logo

    Get the next $ARAV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARAV

    DatePrice TargetRatingAnalyst
    4/17/2023$12.00Buy
    BTIG Research
    6/3/2022$15.00Buy
    ROTH Capital
    More analyst ratings

    $ARAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research resumed coverage on Aravive with a new price target

      BTIG Research resumed coverage of Aravive with a rating of Buy and set a new price target of $12.00

      4/17/23 9:01:46 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH Capital initiated coverage on Aravive with a new price target

      ROTH Capital initiated coverage of Aravive with a rating of Buy and set a new price target of $15.00

      6/3/22 9:00:32 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Aravive with a new price target

      BTIG Research initiated coverage of Aravive with a rating of Buy and set a new price target of $26.00

      3/15/21 8:09:54 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    SEC Filings

    See more
    • SEC Form 15-12G filed by Aravive Inc.

      15-12G - Aravive, Inc. (0001513818) (Filer)

      2/8/24 7:00:50 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Aravive Inc.

      EFFECT - Aravive, Inc. (0001513818) (Filer)

      2/2/24 12:15:24 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Aravive Inc.

      EFFECT - Aravive, Inc. (0001513818) (Filer)

      2/2/24 12:15:15 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Petrini Maria Carolina

      4 - Aravive, Inc. (0001513818) (Issuer)

      4/11/23 4:07:42 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Petrini Maria Carolina

      3 - Aravive, Inc. (0001513818) (Issuer)

      4/11/23 4:07:00 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mcintyre Gail Frances

      4 - Aravive, Inc. (0001513818) (Issuer)

      2/2/23 4:25:16 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aravive, Inc. to Delist from The Nasdaq Stock Market

      HOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market ("Nasdaq")  and, based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and suspend its public reporting obligations. As previously disclosed, at the Company's 2023 annual stockholder's meeting, the stockholders of the Company approved effecting a transfer and assignment of all or substantially all of the Company's assets to an assignee for the benefit

      1/17/24 4:09:41 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer

      Trial did not meet primary endpoint of progression-free survivalCash at the end of Q2 of approximately $18M (unaudited) is expected to be sufficient to fund operations into early Q4 2023 HOUSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that its Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre-specified subset of patients naïve to prior bevacizumab treatment. The trial did not show any differen

      8/2/23 4:01:00 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023

      HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the acceptance of two abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held October 20-24, 2023 in Madrid, Spain. Posters will feature clinical data from the Company's ongoing Phase 1b/2 trials of batiraxcept in clear cell renal cell carcinoma (ccRCC) and pancreatic adenocarcinoma (PDAC). Presentation Details: Title:Phase 1b/2 Study of Batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in Combination with Cabozantinib (Cabo)

      7/28/23 7:05:00 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Financials

    Live finance-specific insights

    See more
    • Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma

      7 of 16 (44%) patients achieved best overall response of partial responseConfirmed response in 5 of 7 (71%) patients who had at least 16 weeks of follow-up14 of 16 (88%) patients demonstrated tumor decrease from baselineBatiraxcept has been well-tolerated with no dose-limiting toxicitiesConference call and webcast today at 8:30 a.m. ET HOUSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patie

      11/12/21 7:00:00 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting

      3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baselineBatiraxcept has been generally well-tolerated with no dose-limiting toxicitiesAravive to host conference call and webcast on November 12 at 8:30 a.m. ET to discuss updated data HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patients with clear cell renal cell carcinoma (

      11/9/21 8:00:00 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care